Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here’s Why the Streak Looks Safe.

Source The Motley Fool

Key Points

  • It's also seeing rising sales from liver disease and oncology products.

  • Gilead recently raised full-year guidance for revenue and EPS.

  • The cash dividend payout ratio is conservative at less than 30%.

  • 10 stocks we like better than Gilead Sciences ›

Gilead Sciences (NASDAQ:GILD) increased its dividend by 3.8% this year, the 11th consecutive year of dividend increases. Its dividend yield is above average, at 1.94%, based on the stock's current price.

The company holds a dominant position in HIV therapies, and these drugs provide dependable cash flow for the near future. Gilead is also seeing expansions into other areas, including oncology, liver, and inflammation therapies.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

There are three reasons why Gilead's dividend is a safe bet to continue to grow.

Medical researchers in a lab.

Image source: Getty Images.

Strong cash flows, low payout ratio

Over nine months, Gilead produced $10.6 billion in free cash flow, up 68% year over year, leaving its cash dividend payout ratio at just below 30%. Spending less than a third of its cash flow on its dividend leaves this pharmaceutical company with plenty of funds to buy back stock, fund research and development, and increase its dividend.

Patents protect its HIV franchise

The company's lead drug, Biktarvy, brought in $4.1 billion in the third quarter, up 10% year over year. It commands a 53% U.S. market share and holds patent exclusivity through 2036.

In the meantime, its newer HIV therapies, such as Yeztugo and Descovy, are rapidly improving sales. Descovy revenue rose 49% year over year to $1 billion in the third quarter, and Yeztugo's sales jumped 682% from the same period a year ago to $305 million.

Gilead is diversifying its revenue streams

While HIV therapies remain its primary revenue source, the company has worked hard to broaden its portfolio.

Breast cancer drug Trodelvy has become a blockbuster product, one of seven Gilead medications that bring in more than $1 billion a year. Trodelvy recently obtained European approval in combination with pembro to treat first-line PD-L1-positive metastatic triple-negative breast cancer. The therapy brought in $506 million in the third quarter, up 42% over the same period a year ago.

Gilead has seven clinical-stage antibody-drug conjugate oncology programs in the pipeline.

The company reported revenue of $203 million in the quarter for liver disease treatment Livdelzi, up 93% year over year. Gilead's pipeline includes 49 clinical programs, including more than a dozen inflammation and immunology candidates such as emvistegrast, which showed strong phase-2 response rates in ulcerative colitis.

Should you buy stock in Gilead Sciences right now?

Before you buy stock in Gilead Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Spot Gold Breaches Four Key Levels, Putting $3,500 at Risk as Technicals Enter Oversold Alert Zone International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
Author  TradingKey
Nov 20, Fri
International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 20, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
Author  Mitrade
Nov 20, Fri
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
placeholder
TradingKey Daily Market Brief: Three Major US Indexes Drop Over 2%, Anthropic Gains 17% on DebutTracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
Author  TradingKey
Nov 20, Fri
Tracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
Nov 19, Thu
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
Nov 19, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
goTop
quote